{"product_id":"sybx-ansoff-analysis","title":"(SYBX) Synlogic, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplore the Complete Growth Strategy Behind the Preview\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Synlogic, Inc. Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification in a concise, actionable format for strategy, investing, or research. The page contains a real preview\/sample of the analysis so you can evaluate style and substance before buying. Purchase the full version to unlock the complete, ready-to-use Ansoff Matrix tailored to Synlogic, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSYNB1618 Phase II PKU in the U.S.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSYNB1618’s Phase II PKU program in the U.S. is a clear market penetration play: it stays in the same rare-disease field and pushes deeper into the existing specialist network that already treats PKU. PKU affects about 1 in 25,000 to 1 in 30,000 births, so progress in these centers can lift trial reach and physician familiarity without entering a new market. That keeps Synlogic, Inc. focused on the current asset and its current U.S. investigator base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSYNB1934 Phase II PKU in the U.S.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSYNB1934 can deepen Synlogic’s reach in the same PKU niche, where the U.S. patient pool is only about 16,000 and treatment choices stay limited. A second Phase II PKU asset increases contact with the same prescribers and patients, which can raise awareness and keep Synlogic in the conversation longer. That helps defend share in a rare-disease market where every new trial readout matters.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral non-systemic PKU positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSynlogic, Inc.'s oral, non-systemic PKU profile is a strong market-penetration edge because it fits a chronic disease setting where patients need long-term, low-burden treatment. PKU affects about 1 in 10,000-15,000 newborns, so a differentiated oral option could matter to a focused clinical base. The non-systemic design may also help adoption at metabolic centers that already manage strict diet therapy and lifelong monitoring.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S. rare-disease site recruitment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSynlogic, Inc. can deepen U.S. market penetration by activating metabolic-disease and rare-disease sites already tied to PKU and related inborn errors. PKU is rare, often cited near 1 in 25,000 U.S. births, so wider site coverage can speed screening, improve enrollment, and lift data generation without changing the indication.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore active sites, faster enrollment\u003c\/li\u003e\n\u003cli\u003eSame indication, deeper U.S. reach\u003c\/li\u003e\n\u003cli\u003eBetter data flow for PKU trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRoche and Ginkgo execution support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSynlogic can use its links with F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc., and Ginkgo Bioworks to speed execution in the current pipeline, since Roche’s global development scale and Ginkgo’s platform work add technical depth and credibility. That can help keep programs visible in the same therapeutic space and support faster research decisions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse Roche ties to support clinical execution.\u003c\/li\u003e\n\u003cli\u003eUse Ginkgo to strengthen technical validation.\u003c\/li\u003e\n\u003cli\u003eKeep focus on the current pipeline.\u003c\/li\u003e\n\u003cli\u003eBoost credibility with existing partners.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSynlogic Deepens U.S. PKU Reach in a Small but Growing Rare-Disease Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSynlogic, Inc.’s market penetration in PKU stays within the same rare-disease niche, using SYNB1618 and SYNB1934 to reach the same U.S. metabolic centers and prescribers. With PKU often cited near 1 in 25,000 births and about 16,000 U.S. patients, even small gains in site coverage can lift awareness and trial depth. The oral, non-systemic profile supports longer use in a chronic setting.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. PKU patients\u003c\/td\u003e\n\u003ctd\u003e~16,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePKU birth rate\u003c\/td\u003e\n\u003ctd\u003e1 in 25,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore play\u003c\/td\u003e\n\u003ctd\u003eDeeper U.S. reach\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing Synlogic, Inc.’s business growth strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Synlogic, Inc. Ansoff Matrix view to quickly align growth options and reduce strategy confusion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of primary and reputable sources to validate Synlogic Ansoff Matrix growth assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSYNB1891 solid tumor entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSYNB1891's intratumoral Phase I program pushes Synlogic, Inc. beyond metabolic disease into solid tumors, so it enters a new oncology market with a new physician network. This widens the addressable clinical community from rare-metabolism specialists to cancer centers and trial oncologists. In Ansoff terms, it is market development: same platform, new therapeutic setting.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSYNB1891 lymphoma entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSYNB1891 moves Synlogic, Inc. into lymphoma, expanding the addressable pool beyond rare metabolic disorders and into a second cancer setting. Lymphoma is a large oncology market, with about 500,000 new cases globally each year. That shift can widen clinical and commercial reach if the platform shows activity in this segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSYNB8802 enteric hyperoxaluria launch path\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSYNB8802’s move into enteric hyperoxaluria is a clear market-development play: one oral, non-systemic asset, now aimed at a 2nd rare metabolic disease beyond PKU. If Synlogic can convert the same platform into 2 indications, it widens reach without rebuilding the drug from scratch. The value case is tied to rare-disease pricing and a smaller, clearer patient pool.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSYNB1353 homocystinuria entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSynlogic’s SYNB1353 homocystinuria entry is a market-development move: it takes the same synthetic-biotic platform into a new inborn-error niche. Classic homocystinuria is rare, at about 1 in 200,000 to 300,000 births, so even small adoption can matter in a high-value specialty market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew patient group\u003c\/li\u003e\n\u003cli\u003eSame core capability base\u003c\/li\u003e\n\u003cli\u003eRare-disease specialty pricing\u003c\/li\u003e\n\u003cli\u003eBroader metabolic reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis expands Synlogic beyond one metabolic segment and can reuse its strain-engineering, manufacturing, and clinical know-how across another orphan indication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMetabolic to immunological condition reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSynlogic’s synthetic biotic platform is designed for both metabolic and immunological diseases, so its market reach can extend beyond its current metabolic focus. That matters because the global immunology drug market was about $170 billion in 2025, versus roughly $100 billion for rare metabolic disease therapies, giving the platform a much wider future pool.\u003c\/p\u003e\n\u003cp\u003eThe Ansoff angle is market development: the same biology can be moved into new specialist disease areas without rebuilding the core tech stack. For Synlogic, that means one platform can support multiple indication paths, but each new entry still needs disease-specific proof, safety, and reimbursement access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMetabolic plus immunology broadens addressable markets.\u003c\/li\u003e\n\u003cli\u003eImmunology is the larger 2025 prize.\u003c\/li\u003e\n\u003cli\u003eNew indications still need clinical proof.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSynlogic Expands Synthetic-Biotic Platform Into Oncology and Rare Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSynlogic, Inc.'s market development is the use of one synthetic-biotic platform across new specialist diseases, especially oncology and rare metabolic disorders. SYNB1891 expands into solid tumors and lymphoma, while SYNB8802 and SYNB1353 extend reach into enteric hyperoxaluria and homocystinuria. The move widens access to new physician networks without changing the core tech.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSYNB1891\u003c\/td\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003eNew tumor setting\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSYNB8802\u003c\/td\u003e\n\u003ctd\u003eEnteric hyperoxaluria\u003c\/td\u003e\n\u003ctd\u003eSecond rare disease\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSYNB1353\u003c\/td\u003e\n\u003ctd\u003eHomocystinuria\u003c\/td\u003e\n\u003ctd\u003eNew orphan niche\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eSynlogic, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSecond PKU candidate SYNB1934\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSYNB1934 is Synlogic, Inc.'s second product candidate for phenylketonuria (PKU), extending the same rare-disease market already targeted by SYNB1618. That is classic product development in the Ansoff Matrix: a new therapy added to an existing customer base. PKU affects about 1 in 23,000 to 25,000 births, so a second option can deepen share in a small, high-need market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHomocystinuria candidate SYNB1353\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSYNB1353 moves Synlogic, Inc. into a new product for homocystinuria, a rare inherited metabolic disease that affects about 1 in 200,000 to 335,000 births. That fits the company’s core rare-metabolism base, so it can deepen its specialty-medicine pipeline without leaving its existing clinical channel. If Synlogic can convert even a small slice of this ultra-rare market, the product can matter because patient pools are tiny but pricing and access can be high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnteric hyperoxaluria candidate SYNB8802\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSYNB8802 is a product development move in Synlogic, Inc.’s Ansoff Matrix: a new oral, non-systemic candidate for enteric hyperoxaluria that extends the company’s rare metabolic disease focus. It adds a differentiated asset to the pipeline and aims at a condition with high unmet need, where current options are limited. The strategy deepens Synlogic’s product set without leaving its core therapeutic area.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOral non-systemic product platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSynlogic, Inc.’s oral non-systemic platform centers on one shared design that can support multiple assets, including SYNB1618, SYNB1934, SYNB1353, and SYNB8802. That lets Synlogic, Inc. reuse the same product architecture across related metabolic and rare-disease markets, which can lower development friction and keep the pipeline aligned.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne oral, non-systemic core\u003c\/li\u003e\n\u003cli\u003eFour named pipeline assets\u003c\/li\u003e\n\u003cli\u003eShared design across markets\u003c\/li\u003e\n\u003cli\u003eSupports portfolio reuse\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePhase progression across the pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSynlogic’s clearest product-development path is stepwise progression: move Phase I assets into Phase II, then deepen Phase II programs where signals are strong. The company already had Phase II phenylketonuria (PKU) programs and Phase I assets in other indications, so pipeline value depends on converting early safety data into mid-stage proof of concept.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdvance Phase I to Phase II\u003c\/li\u003e\n\u003cli\u003eExpand Phase II PKU assets\u003c\/li\u003e\n\u003cli\u003eUse stage gates to de-risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSynlogic Expands Rare-Disease Pipeline With Targeted New Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSynlogic, Inc. uses product development to add new assets to the same rare-metabolism base: SYNB1934 for PKU, SYNB1353 for homocystinuria, and SYNB8802 for enteric hyperoxaluria. PKU affects about 1 in 23,000-25,000 births, while homocystinuria affects about 1 in 200,000-335,000 births.\u003c\/p\u003e\n\u003cp\u003eThis is a tight fit with the Ansoff Matrix: new products, same specialty channel, same oral non-systemic platform. The pipeline stays focused on tiny but high-need markets where even one approved therapy can matter.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003eRare-disease signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSYNB1934\u003c\/td\u003e\n\u003ctd\u003ePKU\u003c\/td\u003e\n\u003ctd\u003e1 in 23,000-25,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSYNB1353\u003c\/td\u003e\n\u003ctd\u003eHomocystinuria\u003c\/td\u003e\n\u003ctd\u003e1 in 200,000-335,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSYNB1891 intratumoral oncology asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSYNB1891 is Synlogic, Inc.'s clearest diversification play: a new product delivered intratumorally, not orally. It targets solid tumors and lymphoma, so it enters a different disease market than Synlogic's metabolic programs. In Ansoff terms, this is the strongest \"new product, new market\" move.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology portfolio expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncology expansion would give Synlogic, Inc. a second lane beside rare-disease assets like PKU and homocystinuria. Cancer is a much bigger pool: GLOBOCAN 2022 estimated 20.0 million new cases and 9.7 million deaths worldwide, with solid tumors making up most of the load. That shifts Synlogic from narrow orphan-market exposure to portfolio-level diversification.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmune-oncology overlap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSYNB1891 can sit at the overlap of oncology and immune-based care, giving Synlogic a route into a new market with a new modality. Synlogic has also signaled interest in immunological conditions, so the platform can extend beyond cancer into immune-linked disease areas. That matters because immune-oncology spans a large, growing market and can support broader pipeline value if early data stay strong.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePlatform diversification through new delivery route\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSynlogic, Inc. uses at least 2 delivery routes across its platform: oral, non-systemic programs and intratumoral SYNB1891. That broadens the asset base beyond one use case and one administration model, so the company is not tied to a single market or route. In Ansoff terms, this is platform diversification, and it can lower concentration risk while opening more clinical and commercial paths.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOral and intratumoral routes serve different patients.\u003c\/li\u003e\n\u003cli\u003eTwo routes reduce single-market dependence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRoche and Ginkgo partnership leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSynlogic can use its Roche and Ginkgo Bioworks ties as a low-cost way to test new biology, new targets, and new therapy paths beyond rare disease. In Ansoff terms, that supports product and market development without building every platform from scratch.\u003c\/p\u003e\n\u003cp\u003eThese partner links matter because they add scientific reach, data, and execution capacity, which can shorten the time to explore adjacent programs. That makes diversification more practical than a standalone push.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRoche expands therapeutic reach\u003c\/li\u003e\n\u003cli\u003eGinkgo adds platform scale and biology tools\u003c\/li\u003e\n\u003cli\u003ePartnerships lower expansion risk\u003c\/li\u003e\n\u003cli\u003eSupports moves beyond rare disease\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSYNB1891 Expands Synlogic Into Oncology and Reduces Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSYNB1891 is Synlogic, Inc.'s clearest diversification move: a new intratumoral product for a new market. It targets solid tumors and lymphoma, while Synlogic's legacy programs focus on rare metabolic disease, so it cuts concentration risk and opens oncology upside.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eDiversification\u003c\/td\u003e\n\u003ctd\u003e20.0M new cancer cases, 9.7M deaths in 2022\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235039781129,"sku":"sybx-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/sybx-ansoff-matrix.webp?v=1785733035","url":"https:\/\/dcfanalyst.com\/products\/sybx-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}